Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy.

ABSTRACT:

Background

Estimates of detectable antinuclear antibodies (ANA) prevalence vary widely, from 6% in healthy populations to 50-80% in patients with autoimmune disease. However, there is a lack of evidence about the overall prevalence in inflammatory bowel disease (IBD) and ANA seroconversion after the beginning of biological therapy.

Objectives

The aim of the study was to investigate the overall prevalence of ANA in IBD patients, their relationship with different treatments, clinical outcomes and the seroconversion rate of ANA in patients treated with biological therapy.

Methods

Ambispective observational study including all consecutive IBD patients was carried out. Information about the presence of ANA, disease phenotype, duration, activity, complications, and past and

SUBMITTER: Garcia MJ 

PROVIDER: S-EPMC8894967 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature